Anti-Shigella flexneri 2a, LPS (SHIG-8964)

Leinco Technologies
Product Code: LEI-S243
Product Group: Primary Antibodies
CodeSizePrice
LEI-S243-250ug250 ug£434.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: Mouse IgG1
Antibody Clonality: Monoclonal
Antibody Clone: SHIG-8964
Regulatory Status: RUO
Target Species: Shigella flexneri
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunofluorescence (IF)
Shipping:
2 - 8°C Wet Ice
Storage:
This purified antibody is stable when stored at 2-8°C. Do not freeze.

Further Information

Concentration:
?1.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Long Description:
Shigella flexneri serotype 2a is a specific strain of Shigella flexneri responsible for causing shigellosis, a prominent global gastrointestinal infection. Serotype 2a holds clinical importance due to its prevalence and virulence. Shigella flexneri 2a infections often lead to severe symptoms such as bloody diarrhea, abdominal cramps, and fever1. The lipopolysaccharides (LPS) on the bacterial cell surface play a pivotal role in its pathogenicity by contributing to adhesion, immune evasion, and triggering inflammatory responses in the host. The bacterium's ability to invade the colonic epithelium leads to localized inflammation and tissue damage, causing the characteristic symptoms of shigellosis. Recently, there have been reports of increased transmission of extensively drug-resistant (XDR) Shigella spp. through sexual activity2.
Purity:
?90%
Target:
LPS

References

1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne, and Environmental Diseases. Link 2. Caldera J, Yang S, Uslan DZ. Extensively Drug-Resistant Shigella flexneri 2a, California, USA, 2022. Emerging Infectious Diseases. 2023;29(7):1473-1475. doi:10.3201/eid2907.230465.